{"id":420884,"date":"2021-12-29T00:00:00","date_gmt":"2021-12-29T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0019-2021-biopharma-endometrial-carcinoma-disease-landscape-forecast-g7-2021\/"},"modified":"2026-04-18T23:21:08","modified_gmt":"2026-04-18T23:21:08","slug":"dlsfon0019-2021-biopharma-endometrial-carcinoma-disease-landscape-forecast-g7-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0019-2021-biopharma-endometrial-carcinoma-disease-landscape-forecast-g7-2021\/","title":{"rendered":"Endometrial Carcinoma | Disease Landscape &#038; Forecast | G7 | 2021"},"content":{"rendered":"<p>Chemotherapy and hormonal therapy have been the mainstay treatments of advanced endometrial carcinoma, but treatment is becoming more directed, as a result of tumor analysis. Immune checkpoint inhibitors (e.g., Merck &#038; Co.\u2019s Keytruda) and targeted therapies (e.g., Eisai\u2019s Lenvima) are experiencing uptake. Some agents target specific biomarker-defined populations, such as MSI-H or dMMR, and others target all patients. The approval and uptake of these agents will result in a more-personalized approach to treating advanced endometrial carcinoma. Several agents are also being positioned for the untapped first-line setting (e.g., GSK\/Tesaro\u2019s dostarlimab, Karyopharm\u2019s Xpovio, AstraZeneca\u2019s Lynparza) and will contribute to robust market growth over the 2019-2029 forecast period.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>How large are the clinically and commercially relevant drug-treatable endometrial carcinoma populations, and how will drug-treatment rates change over time?<\/li>\n<li>What is the expected market impact of recent drug approvals, such as Keytruda and Lenvima, for endometrial carcinoma?<\/li>\n<li>Which pipeline products are poised to become options for the treatment of endometrial carcinoma, and what sales \/ uptake will they secure?<\/li>\n<li>What are the key drivers and constraints in the endometrial carcinoma market, and how will the major markets evolve over the ten-year forecast period?<\/li>\n<\/ul>\n<p><strong>Content Highlights<\/strong><\/p>\n<p>Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.<\/p>\n<p>Primary research: 19 country-specific interviews with thought-leading medical oncologists.<\/p>\n<p>Epidemiology: Diagnosed incident of endometrial carcinoma by country, disease stage, and risk status.<\/p>\n<p>Forecast: 10-year, annualized, drug- and regimen-level sales and patient share of key endometrial cancer therapies through 2029, segmented by brands \/ biosimilars \/ generics, disease stage, and country.<\/p>\n<p>Emerging therapies: Phase III\/PR: 5 drugs; coverage of select early-phase products.<\/p>\n<p><strong>Product Description<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution Enhancement<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast <\/em>will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n","protected":false},"template":"","class_list":["post-420884","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/420884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/420884\/revisions"}],"predecessor-version":[{"id":576289,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/420884\/revisions\/576289"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=420884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}